Open Orphan #ORPH – Successful completion of PrEP Biopharm Toxicology study for respiratory ‘viral mimic’
Phase IIb study to validate efficacy of PrEP-001 against circulating respiratory viruses such as COVID-19, flu and the common cold Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, announces that drug development company PrEP Biopharm […]
Open Orphan #ORPH – Successful extension of contract with top-3 global pharmaceutical client underpins 2021 revenue growth expectations
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a contract renewal extending its consultancy services with a major top-3 global pharmaceutical client to December 2021. Through the Venn Life Sciences team in the Breda office in […]
Pharma Tech Article – Open Orphan #ORPH – Accelerated Vaccine Development with Human Challenge Studies
Pharma Tech Article – Open Orphan #ORPH – Accelerated Vaccine Development with Human Challenge Studies Pharmaceutical companies worldwide are joining global efforts to combat, diagnose, treat and prevent infections from COVID-19. As we have seen, the search for vaccines and possible treatment to curb the transmission and reduce the mortality and morbidity produced by the virus […]
Open Orphan #ORPH subsidiary Venn Life Sciences wins two new contracts
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce its subsidiary Venn Life Sciences (“Venn”) has been awarded two new contracts. The first contract, which will commence immediately, is a COVID-19 […]
Open Orphan #ORPH Announces New £2.5m Influenza Challenge Study Contract Win
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce the signing of a £2.5 million contract by hVIVO, a subsidiary of Open Orphan, to conduct an Influenza human challenge study with […]
Daily Mail – Stock Watch Open Orphan #ORPH October 30th
Daily Mail Stock Watch – Open Orphan #ORPH – October 30th 2020
Open Orphan #ORPH – New 2-year contract with a tier 1 German pharmaceutical company
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new 2-year contract with a tier 1 German pharmaceutical company which is one of Europe’s top research-driven pharmaceutical companies. The contract guarantees […]
Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4
Open Orphan Plc, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical studies is pleased to announce its interim results for the six months ended 30 June 2020. The interim results include the first six months of hVIVO group (“hVIVO”) following its […]
Open Orphan #ORPH – New £4.3m Challenge Study Contract Win with Global Top 10 Vaccine Company
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new £4.3 million contract to conduct a human viral challenge study utilising one of our 8 traditional challenge study models for another […]
Open Orphan #ORPH – Venn Life Sciences New Contract Win
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce Open Orphan’s Paris subsidiary Venn Life Sciences (“Venn”) has secured an important new contract to support a major European pharmaceutical company. The […]